Friday, May 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Intravenous Brincidofovir May Improve Countermeasure’s Tolerability

by Global Biodefense Staff
November 22, 2016
Biodefense News - Industry Updates

Broad-spectrum antiviral Brincidofovir has shown favorable tolerability in its intravenous formulation, according to preclinical data presented by Chimerix at the American Association of Pharmaceutical Scientists‘ Annual Meeting.

Brincidofovir has received Fast Track designation from the FDA for adenovirus, cytomegalovirus (CMV) and smallpox.

Data from the preclinical study showed that oral administration of brincidofovir provided consistent drug exposure to organs that are often the target of viral infection, such as the liver and kidney, but delivered much higher drug exposures in the small intestine than in other anatomical sites. In contrast, the new intravenous formulation of brincidofovir demonstrated much lower, yet constant exposure levels to the small intestines.

The IV formulation delivered more uniform drug exposure levels to key organs including the small intestine, liver and kidney. Importantly, IV administration of brincidofovir resulted in higher central nervous system concentrations, which may support testing of this formulation in viral infections in the brain.

“Data from this study demonstrate limited gastrointestinal exposure with the intravenous formulation of brincidofovir,” said M. Michelle Berrey, MD, MPH, President and CEO of Chimerix. “Clinical studies of this formulation will allow us to determine if the gastrointestinal side-effects observed in prior studies of oral brincidofovir can now be addressed, while maintaining antiviral efficacy.”

As the new IV formulation of brincidofovir progresses in clinical studies, brincidofovir remains in development as an orally-administered lipid conjugate nucleotide for the treatment of adenovirus in hematopoietic cell transplant recipients and other immunocompromised patients, and as a medical countermeasure for the treatment of smallpox.

Chimerix is a biopharmaceutical company dedicated to discovering and developing medicines that improve outcomes for immunocompromised patients. Chimerix’s proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals in 2014; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus.

Tags: AdenovirusAntiviralsPoxvirusesSmallpox

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC